<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741715</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6911</org_study_id>
    <nct_id>NCT00741715</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-controlled, &quot;Factorial&quot; Design, 12-month Study to Evaluate the Efficacy and Safety of AVE5530 25 mg/Day and 50 mg/Day Co-administered With All Registered Atorvastatin Strengths Ranging From 10 mg to 80 mg in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is assessing the efficacy and safety of AVE5530 (25mg and 50mg)
      co-administered with all approved doses of atorvastatin in a double-blind comparison with
      placebo, AVE5530 alone and atorvastatin alone in the management of patients with primary
      hypercholesterolemia. The main objective is to evaluate the effects of the association
      AVE5530+atorvastatin on LDL-C level reduction after 12 weeks of treatment. The effects of
      AVE5530+atorvastatin on other lipid parameters will be assessed as secondary objectives
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include a 2 week pre-randomization placebo lead-in phase. There will be a 12-
      week double-blind treatment period for both components AVE5530 and atorvastatin, followed by
      a 40-week period with maintenance of double-blind design for AVE5530 component and open label
      for atorvastatin component transitioning at 20 mg for all patients with subsequent titration,
      if necessary, based on regular LDL-cholesterol monitoring. The treatment period can be
      variably extended up to approximately 18 months with double-blind for AVE5530 component and
      open-label for atorvastatin.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in calculated LDL-C</measure>
    <time_frame>At week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in calculated LDL-C</measure>
    <time_frame>At 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in total cholesterol, HDL-C, TG, Apo-A1, Apo-B and CRP</measure>
    <time_frame>At week 12, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">1736</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVE5530 25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVE5530 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin 10mg + AVE5530 25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin 10mg + AVE5530 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin 20mg + AVE5530 25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin 20mg + AVE5530 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin 40mg + AVE5530 25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin 40mg + AVE5530 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin 80mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin 80mg + AVE5530 25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin 80mg + AVE5530 50mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVE5530</intervention_name>
    <description>oral administration once daily in the evening with dinner</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>9</arm_group_label>
    <arm_group_label>11</arm_group_label>
    <arm_group_label>12</arm_group_label>
    <arm_group_label>14</arm_group_label>
    <arm_group_label>15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>oral administration once daily in the evening with dinner</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>9</arm_group_label>
    <arm_group_label>10</arm_group_label>
    <arm_group_label>11</arm_group_label>
    <arm_group_label>12</arm_group_label>
    <arm_group_label>13</arm_group_label>
    <arm_group_label>14</arm_group_label>
    <arm_group_label>15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral administration once daily in the evening with dinner</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with high cholesterol levels either not receiving or willing and able to
             discontinue ongoing lipid-lowering therapy

        Exclusion Criteria:

          -  LDL-C levels &gt; 250 mg/dL (6.48 mmol/L)

          -  Triglycerides levels &gt; 350mg/dL (3.95 mmol/L)

          -  Conditions / situations such as:

               -  presence of any clinically significant uncontrolled endocrine disease known to
                  influence lipids levels

               -  Active liver disease

               -  High estimated risk of Coronary Heart Disease

               -  Recent history of congestive heart failure , of unstable angina pectoris,
                  myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or
                  severe peripheral artery disease

               -  Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or
                  Known to be Human Immunodeficient Virus (HIV) positive

          -  Pregnant or breast-feeding women,

          -  Women of childbearing potential not protected by effective contraceptive method of
             birth control (including oral contraceptives) and/or who are unwilling or unable to be
             tested for pregnancy prior to exposure to the Investigational Product

          -  Hypersensitivity to any component of atorvastatin

          -  Concurrent administration of Cytochrome P450 3A4 inhibitors (e.g. cyclosporine,
             erythromycin, clarithromycin, and azole antifungals) should be avoided as increasing
             the risk of myopathy with atorvastatin

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Davidson Michael, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research - 515 North State Street Suite 2700 Chicago Illinois (US)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Puerto Rico</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <disposition_first_submitted>April 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 15, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2016</disposition_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

